Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on InVivo Therapeutics Holdings Corp.

NEW YORK, NY--(Marketwire - Dec 21, 2011) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview^® (EIO^®) on InVivo Therapeutics Holdings Corp. (OTCBB: NVIV). The full 56-page report can be found at www.crystalra.com.

InVivo Therapeutics Holdings Corp. ("InVivo" or "the Company") is a development-stage medical device company. Its lead initiative is to commercialize improved treatments for spinal cord injuries (SCIs) using innovative biomaterials that restore function. InVivo estimates that up to 90% of patients with an acute SCI are in spinal shock immediately following traumatic SCI, but are not permanently paralyzed. It is often the secondary injuries that occur in response to trauma -- bleeding, inflammation, and scarring -- that lead to paralysis.

Thus, InVivo aims to improve the prognosis of SCI patients by helping the spinal cord heal itself before secondary damages, including paralysis, take effect. To do so, the Company has developed a resorbable biopolymer scaffolding medical device composed of restorable biopolymer scaffolding, which is a type of biomaterial used extensively in the medical field for tissue engineering. InVivo's device is designed for implantation or injection into the damaged spinal cord as an adjunct to standard screw-rod procedures when SCI patients are admitted to the hospital. The scaffold serves to protect the spinal cord and promote neuroplastic recovery in the remaining healthy tissue.

As well, the scaffoldings serve as a vehicle for the controlled delivery of anti-inflammatory pharmaceuticals and regenerative cell therapies directly to the injury site. This technology, based on several decades of research at MIT's Langer Lab, has shown effect in preclinical studies at treating the spinal cord and is being advanced into clinical development. InVivo plans to begin a clinical-stage pilot study in 2012.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality research on small- and mid-cap companies. The firm is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street and for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star Ranked for top biotechnology stock performance by Starmine.

Crystal Research Associates' unique and novel product, the Executive Informational Overview^® (EIO^®), is free of investment ratings, target prices, and forward-looking financial models. The EIO^® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO^® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto. The Company has agreed to compensate Crystal Research Associates in cash of forty-two thousand five hundred dollars and one hundred fifty thousand restricted shares for its service in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.